This is a working overview of circular dichroism, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
==== Body fluids ==== Cocaine and its major metabolites may be quantified in blood, plasma, or urine to monitor for use, confirm a diagnosis of poisoning, or assist in the forensic investigation of a traffic or other criminal violation or sudden death. Most commercial cocaine immunoassay screening tests cross-react appreciably with the major cocaine metabolites, but chromatographic techniques can easily distinguish and separately measure each of these substances. When interpreting the results of a test, it is important to consider the cocaine usage history of the individual, since a chronic user can develop tolerance to doses that would incapacitate a cocaine-naive individual, and the chronic user often has high baseline values of the metabolites in his system. Cautious interpretation of testing results may allow a distinction between passive or active usage, and between smoking versus other routes of administration.
=== Apodization in digital audio === An apodizing filter can be used in digital audio processing instead of the more common brick-wall filters, in order to reduce the pre- and post-ringing that the latter introduces.
=== Expansion and diversification === In 1975, UPS moved its headquarters to Greenwich, Connecticut, and began serving all of the 48 contiguous states of the United States. This expansion of operations made UPS the first package delivery company to serve every address in the contiguous United States. Additionally in 1975, UPS went international by establishing operations in Canada. In 1976, UPS established a domestic operation in West Germany. UPS Next Day Air Service was launched in 1985 for all 48 contiguous states plus Puerto Rico. In 1988, UPS Airlines was launched with authorization from the Federal Aviation Administration and became the fastest-growing airline in FAA history – currently the 10th largest airline in the United States. Domestic air service was added to Germany in 1989. In 1991, UPS relocated its headquarters to Sandy Springs, Georgia, a suburb of Atlanta. Following this in 1992, UPS acquired both Haulfast and Carryfast and rebranded them into UPS Supply Chain Solutions. Haulfast provided the pallet haulage and trucking network for the CarryFast group of companies. By 1993, UPS was delivering up to 11.5 million packages and documents per day. In order for the company to service the large volume of customers in 1991, UPS developed technologies to improve efficiency. A handheld device named the "Delivery Information Acquisition Device" (DIAD) was created to record and upload delivery information to the UPS network immediately upon pickup by every UPS driver. In 1992, UPS began tracking all ground shipments electronically.
Sources: en.wikipedia.org
==== Sex differences ==== In humans, oxytocin differentially affects males and females. Females who are administered oxytocin are overall faster in responding to socially relevant stimuli than males who receive oxytocin. Additionally, after the administration of oxytocin, females show increased amygdala activity in response to threatening scenes; however, males do not show increased amygdala activation. This phenomenon can be explained by examining the role of gonadal hormones, specifically estrogen, which modulate the enhanced threat processing seen in females. Estrogen has been shown to stimulate oxytocin release from the hypothalamus and promote receptor binding in the amygdala. It has also been shown that testosterone directly suppresses oxytocin in mice. This has been hypothesized to have evolutionary significance. With oxytocin suppressed, activities such as hunting and attacking invaders would be less mentally difficult as oxytocin is strongly associated with empathy.
One case of prophylactic delivery involving PLGA is for the antibiotic vancomycin, which is typically injected after brain surgery to prevent infections from bacteria including Staphylococcus aureus. Dental scaffolds and bone regeneration: PLGA has been used in periodontal and dental applications, specifically scaffolds and barrier membranes for bone and tissue regeneration. Cancer immunotherapy: PLGA has emerged as a platform for modulating tumors microenvironments. By encapsulating or conjugating drugs (ex: Doxorubicin) to PLGA, researchers try to overcome drug resistance and minimize cytotoxicity compared to free drug releases.
Monazite is a rare-earth-element phosphate mineral, with the chemical formula e.g. (Ce, La, Nd, Th, Y)PO4. It appears in a small amount as an accessory mineral in many igneous, metamorphic and sedimentary rocks. Monazite minerals contain significant amounts of radioactive elements Th and U, which trigger radioactive processes. These two elements are what make this mineral suitable for radiometric dating. In the radioactive processes, the three unstable parent isotopes decay into their respective stable daughter isotopes of Pb. Each following a decay chain consisting of alpha and beta decays, parent isotopes 238U, 235U and 232Th, decay into a series of intermediate daughter isotopes, and finally lead to stable isotopes, 206Pb, 207Pb and 208Pb, respectively. Each decay chain has a unique half-life, which means the daughter isotopes are generated at different rates. The decay processes can be simplified as the following equations, which omit all the intermediate daughter isotopes.
Regorafenib is administered orally for the treatment of colorectal cancer, gastrointestinal stromal cancer and hepatocellular carcinoma. Nintedanib is used for the treatment of idiopathic pulmonary fibrosis. Tests for liver function have to be made to modify doses before the therapy can start. Apatinib is used for the treatment of advanced gastric cancer. It is often diagnosed in late stages because there are no early signs or symptoms.
Sources: en.wikipedia.org
High temperature conditions during the initial stages of implantation will increase the impurity diffusion in the substrate and as a result limit the impinging ion saturation, which is required for nanoparticle nucleation. Both the implant temperature and ion beam current density are crucial to control in order to obtain a monodisperse nanoparticle size and depth distribution. A low current density may be used to counter the thermal agitation from the ion beam and a buildup of surface charge. After implantation on the surface, the beam currents may be raised as the surface conductivity will increase. The rate at which impurities diffuse drops quickly after the formation of the nanoparticles, which act as a mobile ion trap. This suggests that the beginning of the implantation process is critical for control of the spacing and depth of the resulting nanoparticles, as well as control of the substrate temperature and ion beam density. The presence and nature of these particles can be analyzed using numerous spectroscopy and microscopy instruments. Nanoparticles synthesized in the substrate exhibit surface plasmon resonances as evidenced by characteristic absorption bands; these features undergo spectral shifts depending on the nanoparticle size and surface asperities, however the optical properties also strongly depend on the substrate material of the composite.
Korolev received word about von Braun's 1956 Jupiter-C test and, mistakenly thinking it was a satellite mission that failed, expedited plans to get his own satellite in orbit. Since the R-7 was substantially more powerful than any of the US launch vehicles, he made sure to take full advantage of this capability by designing Object D as his primary satellite. It was given the designation 'D', to distinguish it from other R-7 payload designations 'A', 'B', 'V', and 'G' which were nuclear weapon payloads. Object D dwarfed the proposed US satellites, having a weight of 1,400 kilograms (3,100 lb), of which 300 kilograms (660 lb) would be composed of scientific instruments that would photograph the Earth, take readings on radiation levels, and check on the planet's magnetic field. However, things were not going along well with the design and manufacturing of the satellite, so in February 1957, Korolev sought and received permission from the Council of Ministers to build a Prosteishy Sputnik (PS-1), or simple satellite. The council also decreed that Object D be postponed until April 1958. The new Sputnik was a metallic sphere that would be a much lighter craft, weighing 83.8 kilograms (185 lb) and having a 58-centimeter (23 in) diameter. The satellite would not contain the complex instrumentation that Object D had, but had two radio transmitters operating on different short wave radio frequencies, the ability to detect if a meteoroid were to penetrate its pressure hull, and the ability to detect the density of the Earth's thermosphere.
While Tl+ is stabilised by the inert-pair effect, this inert pair of 6s electrons is still able to participate chemically, so that these electrons are stereochemically active in aqueous solution. Additionally, the thallium halides (except TlF) are quite insoluble in water, and TlI has an unusual structure because of the presence of the stereochemically active inert pair in thallium.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.